Inventiva to Present Corporate Overview at the Cowen and Company 39th Annual Health Care Conference

6 March 2019

The FDA Grants Rare Pediatric Disease Designation to Odiparcil for the Treatment of MPS VI

5 March 2019

Inventiva Announces Poster Presentation on a Promising Biomarker for MPS VI at the 15th International Symposium on MPS and Related Diseases

26 July 2018

Inventiva announces positive outcomes of biomarker study measuring intracellular GAGs in leukocytes from MPS VI patients

26 February 2018

Inventiva Announces Enrollment of First Patient into Its Odiparcil Phase IIa Trial (iMProveS) for MPS VI

3 January 2018

Inventiva’s Odiparcil Awarded Orphan Drug Designation for the Treatment of MPS VI by the European Medicines Agency

29 August 2017

Odiparcil Awarded Orphan Drug Designation for the Treatment of MPS VI by the FDA

10 August 2017

Inventiva Announces New Compelling Data on Odiparcil/IVA336 to be Presented at MPS Society National Conference

29 June 2017